Clinical Trials
15 trialsNCT03639948 2024-04-11
NeoPACT
University of Kansas Medical Center
Phase 2 Unknown
NCT04739670 2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05266937 2024-02-01
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Consorzio Oncotech
Phase 2 Unknown
NCT03567720 2023-06-01
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
Phase 2 Unknown
NCT05872412 2023-05-25
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase 2 Unknown
NCT03907800 2022-10-27
NeoPATH
Ruijin Hospital
Phase 2 Unknown
NCT05491694 2022-08-08
HIFU
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05438706 2022-06-30
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT02341911 2022-04-20
TNBC
Fudan University
Phase 2 Unknown
NCT04907344 2021-05-28
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT01372579 2019-06-07
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Northwestern University
Phase 2 Unknown
NCT03876886 2019-03-21
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
ChineseAMS
Phase 3 Unknown
NCT01752686 2012-12-25
A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Severance Hospital
Phase 3 Unknown
NCT01378533 2011-12-28
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
ChineseAMS
Phase 3 Unknown
NCT01276769 2011-11-16
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
ChineseAMS
Phase 2 Unknown